Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Atp Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$461,810

329 payments

Through program year 2025, Atp Clinical Research is reported as receiving $461,810 in research payments, across 329 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $117,594 155
2024 Research $2,499 5
2023 Research $256 1
2022 Research $4,217 2
2021 Research $9,269 15
2020 Research $191,316 85
2019 Research $136,660 66

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $259,867 144 payments
  2. Boehringer Ingelheim International GmbH $117,542 154 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $29,621 10 payments
  4. H. Lundbeck A S $23,762 2 payments
  5. Novartis Pharmaceuticals Corporation $17,840 1 payment
  6. ACADIA Pharmaceuticals Inc $7,801 1 payment
  7. Boehringer Ingelheim Canada Ltd.Ltee $2,993 13 payments
  8. AbbVie, Inc. $2,332 3 payments
  9. Eli Lilly and Company $52 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $189,847 111 payments
  2. A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia $117,542 154 payments
  3. A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease $44,484 20 payments
  4. PoC in Prevention of Relapse $24,982 5 payments
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia $21,562 12 payments
  6. Active Reference Fluoxetine Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder MDD $20,762 1 payment
  7. A Randomized Double Blind Placebo Controlled Parallel Group Study to Evaluate the Efficacy of Two Doses of Cnp520 in Participants at Risk for the Onset of Clinical Symptoms of Ad $17,840 1 payment
  8. Acp-103-048 $7,801 1 payment
  9. Connex 2 $4,473 3 payments
  10. A Prospective, Non-Interventional Study to Determine Signs and Symptoms That Impact Daily Life of Patients With Irregular Sleep-Wake Rhythm Disorder and Their Caregivers $3,975 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record